

Appendix

Table of Contents

The Committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma

2013 Edition Preface	8
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations	11
Explanation of surveillance algorithms/diagnostic algorithms for hepatocellular carcinoma	18
Explanation of treatment algorithms for hepatocellular carcinoma	20
Chapter 1 ■ Prevention	24
Introduction	24
Section 1 Interferon Therapy	25
CQ1 Does interferon therapy chronic hepatitis C infection effectively prevent HCC?	25
Section 2 Liver Support Therapy	30
CQ2 Does liver support therapy effectively prevent HCC?	30
CQ3 Does antiviral therapy against chronic hepatitis B infection effectively prevent HCC?	32
Chapter 2 ■ Diagnosis and Surveillance	38
Section 1 Surveillance	38
Introduction	38
CQ4 Who are eligible candidates for surveillance?	39
CQ5 Does surveillance improve prognosis?	46
CQ6 What methods are used in surveillance?	49
CQ7 What size (cm) of atypical liver nodules using dynamic CT or dynamic MRI should be further examined?	54
Section 2 Tumor Markers	56
Introduction	57
CQ8 Is it useful to measure two or more tumor markers for diagnosing HCC?	59
CQ9 Is tumor marker measurement an effective post-treatment indicator for HCC?	61
Section 3 Diagnostic Imaging	61
Introduction	61
CQ10 What are the best tests for diagnosing early-stage HCC in patients with cirrhosis?	62
CQ11 What are the best tests for diagnosing typical HCC in high-risk patients?	69

CQ12 Is angiography necessary before HCC treatment?	75
CQ13 Is CTAP/CTHA necessary before HCC treatment?	79
CQ14 What test methods are useful for diagnosing liver tumors in patients with decreased kidney and liver function?	80
CQ15 How should contrast media be used for diagnostic imaging of HCC?	84
CQ16 Are brain MRI, chest CT, bone scintigraphy, and FDG-PET necessary for determining the stage of HCC?	91
CQ17 Does contrast-enhanced ultrasound improve the ability to diagnose HCC?	94
CQ18 Is contrast-enhanced ultrasound useful for determining the treatment outcomes of percutaneous ablation therapy and TACE?	99
Chapter 3 ■ Surgery	104
Introduction	104
Section 1 Indications for Surgery/Surgical Procedures	107
CQ19 What assessment modalities are appropriate for evaluating liver function prior to liver resection? What are the indications for surgery from the perspective of liver function?	107
CQ20 What is the standard surgical procedure for liver resection?	113
CQ21 What are the indications for liver resection in terms of tumor condition?	118
Section 2 Prognostic Factors	122
CQ22 What are the prognostic factors after liver resection?	122
CQ23 Does the size of the resection margin affect prognosis?	125
CQ24 Does anatomical liver resection affect prognosis?	128
Section 3 Perioperative Management	130
CQ25 Is proactive, perioperative administration of blood products recommended?	130
CQ26 Does hepatic pedicle clamping and decreased central venous pressure decrease bleeding during liver resection?	133
CQ27 Is abdominal drain placement necessary for liver resection?	136
Section 4 Adjuvant Therapy	137
CQ28 Does neoadjuvant chemotherapy improve prognosis after liver resection?	137
CQ29 Does adjuvant chemotherapy improve prognosis after liver resection?	140
Section 5 Liver Transplantation	143
Introduction	143
CQ30 Does pretransplantation tumor downstaging improve the prognosis of liver transplantation?	145
CQ31 What are the indications of liver transplantation for HCC?	148
Chapter 4 ■ Percutaneous Ablation Therapy	156
Introduction	156
CQ32 Who are eligible candidates for percutaneous ablation therapy?	157

CQ33 How should a type of percutaneous ablation therapy be selected?.....	162
CQ34 Does a combination of TACE and percutaneous ablation therapy improve prognosis?	166
CQ35 Are contrast-enhanced ultrasound and fusion imaging useful guides for percutaneous ablation therapy?	169
CQ36 What type of diagnostic imaging is useful for assessing treatment response of percutaneous ablation therapy?	172
Chapter 5 ■ Transcatheter Arterial Chemoembolization (TACE)	175
Introduction	175
CQ37 Who are eligible in TACE/TAE?.....	176
CQ38 What type of embolic material or anticancer agent should be used for TACE/TAE?	184
CQ39 How should repeat TACE/TAE be scheduled?	193
CQ40 What types of diagnostic imaging techniques are useful for evaluation of the treatment effect of TACE?	196
Chapter 6 ■ Chemotherapy	201
Introduction	201
CQ41 Who are eligible candidates for systemic chemotherapy?.....	202
CQ42 Does hepatic arterial infusion chemotherapy improve prognosis?.....	205
CQ43 Which chemotherapy regimens (drug regimens) are effective?	206
CQ44 Is hormone therapy effective?	210
CQ45 What are the predictive and prognostic factors for the treatment outcomes of chemotherapy?	212
CQ46 How should the treatment outcome of chemotherapy be determined?.....	213
CQ47 What are the adverse effects of chemotherapy, and how should they be treated?	215
Appendix table	219
Chapter 7 ■ Radiation Therapy	222
Introduction	222
CQ48 Is three-dimensional (3D) conformal radiation therapy useful for HCC?.....	223
CQ49 Is stereotactic body radiation therapy useful for HCC?.....	228
CQ50 Is particle radiation therapy [proton therapy, heavy particle (carbon ion) radiation therapy] useful for HCC?	232
CQ51 Is radiation therapy indicated for distant metastases from HCC?	235

Chapter 8 ■ Post-Treatment Surveillance, Prevention and Treatment of Recurrence	240
Introduction	240
CQ52 How should patients be followed up after liver resection and percutaneous ablation therapy?	241
CQ53 What methods are effective for preventing recurrence after liver resection and percutaneous ablation therapy?	244
CQ54 What methods are effective for preventing recurrence after liver transplantation?	249
CQ55 What treatments are effective against recurrence after liver transplantation?	253
CQ56 What treatments are effective against recurrence after percutaneous ablation therapy?	258
CQ57 What treatments are effective against recurrence after liver transplantation?	260
 Comments from the Health Economics Committee	
■ Health Economics Perspective on Clinical Practice Guidelines for Hepatocellular Carcinoma, 2013 Edition	
- Regarding CQ43 in Particular -	262
 Literature Search Queries	265